Ceribell, Inc. (CBLL)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$24.72+0.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · CBLL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 6.0% |
| Our one-year growth estimate | diamond | 31.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 25.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
CBLL — earnings miss
Dated 2026-08-10
Results of Operations and Financial Condition. On August 10, 2026, CeriBell, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2026. A copy of the press release, dated August 10, 2026, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference. The foregoing information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall…
Why it matters: Less loss shows better financial health and efficiency. This is important for investor trust.
Supportive ifOperating losses decrease from $19.3 million in Q2 to below $18 million in Q3.
Worry ifOperating losses rise or stay above $19 million in Q3.
Why it matters: An update to revenue guidance shows management is confident in business growth. This can affect how investors feel.
Supportive ifManagement raises revenue guidance for 2026 to more than $117 million.
Worry ifManagement lowers revenue guidance for 2026 to less than $112 million.
Why it matters: Ongoing improvement in gross profit shows better cost management and pricing power. This can boost investor confidence.
Supportive ifGross profit increases above $23.12M in the next quarter.
Worry ifGross profit declines or stays below $23.12M.
Why it matters: Higher gross profit shows better cost control. This can bring in more investors.
Supportive ifGross profit margin goes up compared to earlier quarters.
Worry ifGross profit margin declines or stays flat compared to the last quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$140 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $438 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,052 loss on $10,000 · 30.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Revenue growth below this level may show weak demand or market problems.
Worry ifQ2 revenue growth reported below 26% compared to Q2 2025.
Less concerning ifQ2 revenue growth meets or exceeds 26% compared to Q2 2025.
Why it matters: Confirmation of revenue guidance shows the company is maintaining growth momentum. It will signal strong demand for its products.
Supportive ifManagement expects Q3 revenue to be between $114 million and $117 million.
Worry ifManagement lowers Q3 revenue guidance from the current range.
Why it matters: Better gross margins show improved cost management. This may boost investor confidence.
Supportive ifGross margin is over 92% in Q3 results, showing ongoing improvement.
Worry ifGross margin falls below 90% in Q3 results, suggesting cost issues.
Why it matters: Meeting or exceeding the revenue guidance of $112M to $116M shows strong demand and execution.
Supportive ifQ2 revenue reported above $112 million.
Worry ifQ2 revenue reported below $112 million.
Why it matters: FDA approvals can drive sales and market confidence. New products can expand the customer base.
Supportive ifCeribell receives FDA approval for new product lines by the end of 2026.
Worry ifNo new FDA approvals are announced by year-end.
Why it matters: If sector revenue growth rebounds, it could help Ceribell perform better.
Supportive ifSector revenue growth is showing signs of speeding up toward past highs.
Worry ifSector revenue growth is still slowing down.